The rare, deadly blood clots triggered by an autoimmune response to the COVID-19 vaccines from Johnson & Johnson and ...

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while ...

On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible ...

Novo Nordisk is coming for Roche’s Hemlibra. A phase 3 trial of the Danish drugmaker’s challenger to the blockbuster ...

Atai Life Sciences, one of the leading shareholders in psilocybin drug developer Compass Pathways, is swapping CEOs.

After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a ...

The emerging field of pulsed field ablation continues to pick up speed around the globe, with Medtronic collecting a ...

Results from the phase 3 SUPERNOVA study show that the company’s investigational long-acting antibody (LAA) sipavibart ...

Cytokinetics has set out to prove that aficamten is a threat to Bristol Myers Squibb’s $13.1 billion heart disease drug ...

AC Immune is currently evaluating ACI-24.06 in a phase 1b/2 trial in subjects with prodromal Alzheimer’s disease as well as ...

Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its ...

Sanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side ...